Synapse
⌘+K
Synapse
PulseExploreClubsResearchersJournals
Instagram
HomeClubsExplore
March 12, 2002Proceedings of the National Academy of Sciences

Bombesin antagonists inhibit growth of MDA-MB-435 estrogen-independent breast cancers and decrease the expression of the ErbB-2/HER-2 oncoprotein and c- jun and c- fos oncogenes

View Full Paper
Ask AI
Bookmark
Share

Authors

ABAna M. BajoTulane University
Andrew V. Schally
Andrew V. SchallyUniversity of MiamiMKMagdalena KrupaOncoArendi Therapeutics (Poland)

Discussion

Loading...

Member takes

Implication

Key Points

Key points are not available for this paper at this time.

Cite This Study

Bajo et al. (2002) studied this question.

synapsesocial.com/papers/6a2ef0d8398a7740d47489bfhttps://doi.org/10.1073/pnas.052715299
View Full Paper
Ask AI
Bookmark
Share

Also Consider

Synapse has enriched 3 closely related papers on similar clinical questions. Consider them for comparative context:

  1. 1Immunohistochemical study of the expression of MUC5AC and MUC6 in breast carcinomas and adjacent breast tissues2001 · 44 citations
  2. 2HER-2/neu in node-negative breast cancer: prognostic significance of overexpression influenced by the presence of in situ carcinoma.1992 · 459 citations
  3. 3Inhibition of growth of MDA-MB-468 estrogen-independent human breast carcinoma by bombesin/gastrin-releasing peptide antagonists RC-3095 and RC-3940-II2000 · 32 citations